OTX015

birabresib · Oncoethix GmbH (subsidiary of Merck & Co.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OTX015, covering 2018-10-01 to 2018-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) [Phase 1]

See pricing